Oncology Pharma Statistics
Total Valuation
Oncology Pharma has a market cap or net worth of 3,866.
| Market Cap | 3,866 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Oncology Pharma has 38.66 million shares outstanding.
| Current Share Class | 38.66M |
| Shares Outstanding | 38.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 0.02.
| PE Ratio | 0.02 |
| Forward PE | n/a |
| PS Ratio | 0.38 |
| PB Ratio | -0.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.22 |
| P/OCF Ratio | 0.55 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.88
| Current Ratio | 0.88 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 555.27 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 100.70% |
| Revenue Per Employee | 10,214 |
| Profits Per Employee | 186,035 |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -18.26 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 49.78 |
| Average Volume (20 Days) | 8,996 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.56 |
Income Statement
In the last 12 months, Oncology Pharma had revenue of 10,214 and earned 186,035 in profits.
| Revenue | 10,214 |
| Gross Profit | 10,214 |
| Operating Income | -14,469 |
| Pretax Income | -14,469 |
| Net Income | 186,035 |
| EBITDA | -8,650 |
| EBIT | -14,469 |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 9,311 in cash and 410,900 in debt, giving a net cash position of -401,589 or -0.01 per share.
| Cash & Cash Equivalents | 9,311 |
| Total Debt | 410,900 |
| Net Cash | -401,589 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -220,269 |
| Book Value Per Share | n/a |
| Working Capital | -26,007 |
Cash Flow
In the last 12 months, operating cash flow was 7,058 and capital expenditures -6,318, giving a free cash flow of 740.
| Operating Cash Flow | 7,058 |
| Capital Expenditures | -6,318 |
| Free Cash Flow | 740 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 100.00%, with operating and profit margins of -141.66% and 1,821.37%.
| Gross Margin | 100.00% |
| Operating Margin | -141.66% |
| Pretax Margin | -141.66% |
| Profit Margin | 1,821.37% |
| EBITDA Margin | -84.69% |
| EBIT Margin | -141.66% |
| FCF Margin | 7.24% |
Dividends & Yields
Oncology Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 4,812.08% |
| FCF Yield | 19.14% |
Stock Splits
The last stock split was on October 9, 2020. It was a reverse split with a ratio of 0.01.
| Last Split Date | Oct 9, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Oncology Pharma has an Altman Z-Score of -183.89. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -183.89 |
| Piotroski F-Score | n/a |